Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Smallpox Vaccine Clear all
Completed Phase 2 Interventional

Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

NCT00081835
View directory record Official record
Conditions
Vaccinia
Interventions
NP-016 Vaccine Immune Globulin (IV-VIG)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Year and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults

NCT00026611
View directory record Official record
Conditions
Smallpox
Interventions
Dryvax vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 23, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

NCT00928577
View directory record Official record
Conditions
Smallpox
Interventions
Not listed
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
14,108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
4
States / cities
Twentynine Palms, California • Fort Campbell North, Kentucky • Fort Bliss, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
56 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jul 23, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ACAM2000® Myopericarditis Registry

NCT01395082
View directory record Official record
Conditions
Myocarditis, Pericarditis
Interventions
Not listed
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

NCT00914732
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
8
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537
View directory record Official record
Conditions
Smallpox
Interventions
LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT00189904
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lexington, Kentucky • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Smallpox Vaccine

NCT00046397
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-M
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

NCT00879762
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 23, 2026, 1:33 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, Smallpox and Mpox Vaccine, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 42 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT

NCT00038987
View directory record Official record
Conditions
Smallpox
Interventions
Wetvax (APSV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
4
States / cities
Oakland, California • Iowa City, Iowa • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

NCT00000767
View directory record Official record
Conditions
HIV Infections
Interventions
TBC-3B Vaccine, Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
5
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Combination Study With MVA BN and Dryvax

NCT00082446
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820
View directory record Official record
Conditions
Smallpox
Interventions
ACAM3000 MVA Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 31 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jul 23, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

NCT01540929
View directory record Official record
Conditions
Smallpox
Interventions
Not listed
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
5,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 1:33 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

NCT00103584
View directory record Official record
Conditions
Smallpox
Interventions
LC16m8 Smallpox Vaccine
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years to 34 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
4
States / cities
Stanford, California • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Jul 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

NCT01158157
View directory record Official record
Conditions
Smallpox Vaccine Adverse Reaction
Interventions
ACAM2000
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Altamonte Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 1:33 AM EDT